AllPeptides.eu - Advanced Peptide Research
    Back to BlogImmune & Longevity

    What is Livagen? Mechanism, Benefits, Dosage

    AllPeptides.eu Editorial Team October 12, 2025 Updated: March 27, 2026 16 min read

    Summary

    Livagen is a tetrapeptide bioregulator (KEDA: Lys–Glu–Asp–Ala) investigated for epigenetic actions — specifically, opening condensed chromatin to restore youthful gene expression in aged cells.

    Substance Properties

    AliasesLivagen · KEDA · H‑Lys‑Glu‑Asp‑Ala‑OH
    Family / PathwayPeptide bioregulator · epigenetic chromatin decondensation
    Sequence (AA)Lys–Glu–Asp–Ala (KEDA) — tetrapeptide
    StorageLyophilized: ≤ −20 °C · Solution: 2–8 °C

    What is Livagen?

    Livagen is a short 'bioregulatory' peptide of four amino acids (Lys–Glu–Asp–Ala / KEDA) studied primarily for its ability to relax age-condensed chromatin and normalize gene activity in aged cells.

    Epigenetic actions: Chromatin decondensation

    In experiments on human lymphocytes, Livagen 'deheterochromatinized' DNA and reactivated ribosomal genes. In other models, it regulated digestive enzymes and protected endogenous enkephalins by inhibiting their breakdown — without binding opioid receptors.

    Hepatoprotective and immunomodulatory properties

    In animal models, Livagen exhibited hepatoprotective and immunomodulatory actions. Chromatin decondensation in lymphocytes suggests improved protein synthesis and restoration of normal gene expression rates.

    Enkephalinase inhibition

    A unique property of Livagen is potent inhibition of enzymes that degrade enkephalins (enkephalinases), extending endogenous enkephalin tone associated with stress relief and analgesia. This is achieved without opioid receptor agonism.

    Frequently Asked Questions (FAQ)

    How does Livagen differ from Epithalon?

    Epithalon targets telomerase and the pineal gland, while Livagen focuses on chromatin decondensation and immunomodulation. They serve different goals in the anti-aging spectrum.

    References & Studies

    1. Khavinson VK et al. Effect of Livagen peptide on chromatin activation. Bull Exp Biol Med. 2002;134(5):421-424.

    Disclaimer

    This article is exclusively educational for researchers. It does not constitute medical advice.

    Educational contentRegularly reviewed & maintainedEvidence-based review
    Published: October 12, 2025 Updated: March 27, 2026 Author: AllPeptides.eu Editorial Team

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu